Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tri-split Face Study of Skin Resurfacing for Melasma
NCT02892071Phase 1Withdrawn
- Start
- Dec 2020
- Primary completion
- Sep 2022
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of trichloroacetic acid in melasma (3 arms). Primary endpoint: modified Melasma Area and Severity Index at 6 months. Planned start Dec 2020; status: withdrawn.
02
Drugs
trichloroacetic acid
03
Conditions
melasma
Beyond the preview
Go deeper on NCT02892071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892071.